... of existing products and future revenues from new drugs. Gilead has 3 complete once-daily single tablet drugs for HIV/AIDS, each with a different combination of 3 to 4 antiviral compounds. The first product, Atripla, was approved in 2010, followed ...
http://seekingalpha.com/article/1832192-gilead-five-year-revenue-outlook-part-1?source=feed
http://seekingalpha.com/article/1832192-gilead-five-year-revenue-outlook-part-1?source=feed
No comments:
Post a Comment